76 results on '"Raz, Itamar"'
Search Results
2. Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study
3. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
4. GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS
5. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
6. RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
7. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
8. ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
9. Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy
10. Adolescent cognitive function and incident early-onset type 2 diabetes
11. Management of diabetic neuropathy
12. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58
13. Causes and Risk Factors for Death in Diabetes
14. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa
15. Reply to the letter of Draves et al. In response to the article: “Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization” (Kesavadev et al.)”
16. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization
17. EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
18. PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE
19. SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply
20. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
21. DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
22. NATRIURETIC PEPTIDES VERSUS A CLINICAL HISTORY OF HEART FAILURE FOR RISK PREDICTION IN PATIENTS WITH DIABETES
23. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)
24. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
25. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L)
26. The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?
27. Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System
28. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
29. The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?
30. INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53
31. Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis
32. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial
33. Different effects of bariatric surgical procedures on dyslipidemia: a registry-based analysis
34. BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
35. RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK
36. CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
37. PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL
38. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c
39. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care
40. BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
41. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
42. Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus
43. Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients
44. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
45. Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial
46. The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients – A randomized controlled trial
47. Effects of Moderate Intensity Glycemic Control After Cardiac Surgery
48. Serum adiponectin is associated with homocysteine in elderly men and women, and with 5,10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner
49. PL-218: The weight loss or the procedure? Effect of different bariatric operations on hyperlipidemia
50. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.